Stem Cell Transplantation Unit, Department of Hematology, Faculty of Medicine, Ankara University, Cebeci Campus, 06590 Ankara, Turkey.
Ann Hematol. 2012 Apr;91(4):577-86. doi: 10.1007/s00277-011-1349-2. Epub 2011 Oct 5.
This retrospective case-matched study evaluated the efficacy of reduced intensity conditioning (RIC) regimen on early and late allogeneic transplant outcome in chronic myeloid leukemia (CML) patients. Twenty-eight patients conditioned with RIC regimen were matched to 56 patients who received a myeloablative conditioning (MAC) regimen. The main criteria for case matching among our CML allotransplant cohort were the Gratwohl scoring system. The median score was 2 (1-4) in each group. The pretransplant disease status was first chronic phase (CP1, n = 20), CP2 (n = 2), and advanced phase (n = 6) in RIC, and CP1 (n = 46), CP2 (n = 3), and advanced phase (n = 7) in MAC. The duration of neutropenia and thrombocytopenia was shorter in RIC than MAC. The grade and duration of mucositis were less in RIC. The need for total parenteral nutrition (21% vs. 77%, p < 0.0001) and febrile neutropenic episodes (50% vs. 95%, p < 0.0001) were observed less frequently in RIC compared with MAC-given patients. Acute or chronic graft versus host diseases (GvHD) were not affected by the intensity of conditioning regimen. The incidence of transplant-related mortality was higher in MAC (7% vs. 14%, p = 0.01). Although more relapse/progression was observed in the RIC group, the probability of 5- and 10-year leukemia-free- and overall survival were similar regardless of conditioning regimen intensity (p > 0.05). In early first CP, the pair of female donor-male recipient and the development of chronic GvHD prolonged both leukemia-free survival and overall survival in multivariate analysis. According to our single-center matched-pair analysis, the use of RIC regimens in patients with low-risk CML results with toxicities less, responses later, and relapses more frequent than the MAC regimens.
这项回顾性病例匹配研究评估了在慢性髓系白血病 (CML) 患者中,降低强度的预处理(RIC)方案对早期和晚期同种异体移植结果的疗效。28 例接受 RIC 方案预处理的患者与 56 例接受清髓性预处理(MAC)方案的患者进行了匹配。我们的 CML 异基因移植队列中病例匹配的主要标准是 Gratwohl 评分系统。每组的中位数评分为 2(1-4)。RIC 组患者的预处理前疾病状态为慢性期 1 期(CP1,n=20)、CP2(n=2)和进展期(n=6),MAC 组患者的预处理前疾病状态为 CP1(n=46)、CP2(n=3)和进展期(n=7)。RIC 组中性粒细胞减少和血小板减少的持续时间短于 MAC 组。RIC 组的粘膜炎程度较轻,持续时间较短。RIC 组总肠外营养(21% vs. 77%,p<0.0001)和发热性中性粒细胞减少症(50% vs. 95%,p<0.0001)的发生率低于 MAC 组。急性或慢性移植物抗宿主病(GvHD)不受预处理方案强度的影响。MAC 组的移植相关死亡率较高(7% vs. 14%,p=0.01)。尽管 RIC 组观察到更多的复发/进展,但无论预处理方案强度如何,5 年和 10 年无白血病生存率和总生存率的概率相似(p>0.05)。在早期 CP1 中,女性供体-男性受者配对和慢性 GvHD 的发展,在多变量分析中延长了无白血病生存率和总生存率。根据我们的单中心匹配对分析,RIC 方案在低危 CML 患者中的应用导致毒性降低、反应延迟和复发更频繁,而 MAC 方案则相反。